The most prepared men were the most satisfied with recovery of postoperative urinary function and experiences surrounding surgery, and felt expectations had been met.
Clinicians and patients are often concerned that biopsies miss occult high-grade prostate cancer. This study helps affirm that with a negative confirmatory biopsy, active surveillance is the right choice.
A recent Cleveland Clinic study revealed for the first time that the molecular features of a low-grade tumor as measured by genomic testing, rather than the amount of tumor present on biopsy, can identify which cancers should be treated and which are safe to watch.
Two postdoctoral fellows in the laboratory of Nima Sharifi, MD, have received prestigious Department of Defense Prostate Cancer Research Program Early Investigator Research Awards in support of innovative prostate cancer work.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Recruitment underway to bring additional leading scientists to expanding GU cancer research program at Cleveland Clinic.
Adding brachytherapy to external beam radiotherapy appears to improve survival outcomes for men with high-risk prostate cancer.
Urologist Robert Abouassaly, MD, MSc, says the specialty continues to shift the risk-benefit ratio in favor of the patient.
A new study found that adjuvant radiotherapy (ART) for high-risk post-prostatectomy patients is associated with superior outcomes compared to early-salvage radiotherapy (ESRT) along three key parameters.
Though the wait is on for the data to mature, apalutamide could lead to survival improvement in a significant number of patients and a major impact on treatment of patients with M0CRPC.
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.